Medaysis
Enable Innovation

DATA SHEET

Mouse Anti-BRAF V600E [MD47]: MC0129

Intended Use: For Research Use Only

Description: Serine/threonine-protein kinase B-raf (BRAF) is a member of the Raf family. BRAF mutations are frequent in benign and malignant human tumors. BRAF V600E mutation accounts for the vast majority of BRAF alterations and the mutation induces a conformational change of the activation segment leading to a constitutive kinase activity of BRAF and consecutive phosphorylation of downstream targets. BRAF V600E mutation have been detected in melanoma, papillary thyroid carcinoma, pleomorphic xanthoastrocytomas, Langerhans cell histiocytosis, borderline ovarian cancer, ganglioglioma, colorectal carcinoma, and pilocytic astrocytoma.

Specifications:

Clone:	MD47
Source:	Mouse
Isotype:	IgG2b
Reactivity:	Human, mouse, rat
Immunogen:	Synthetic peptide from the internal region of human BRAF V600E
Localization:	Cytoplasm
Formulation:	Purified antibody in PBS pH7.4, containing BSA and ≤ 0.09% sodium azide (NaN3)
Storage:	Store at 2°- 8°C
Applications:	IHC, ELISA, IP, WB

Package:

Description	Catalog No.	Size
BRAF V600E Concentrated	MC0129	1 ml

IHC Procedure*:

Positive Control Tissue:	Colon carcinoma with BRAF V600E mutation
Concentrated Dilution:	10-50
Pretreatment:	Tris EDTA pH9.0, 15 minutes Pressure Cooker or 30-60 minutes water bath at 95°-99°C
Incubation Time and Temp:	Overnight @ 4°C
Detection:	Refer to the detection system manual

* Result should be confirmed by an established diagnostic procedure.



FFPE human melanoma stained with anti-BRAF V600E using DAB

References:

1. Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma human pathology. February Volume 46, Issue 2, Pages 169–175, 2015.
2. Immunohistochemistry as a quick screening method for clinical detection of BRAF(V600E) mutation in melanoma patients. Tumor Biology. Volume 35, Issue 6, pp 5727-5733, 2014.
3. Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma. Mod Pathol. Mar;26(3):414-20, 2013.
4. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas human pathology. November Volume 44, Issue 11, Pages 2563–2570, 2013.

Orders: customercare@medaysis.com Support: techsupport@medaysis.com Tel: 510-509-3153 www.medaysis.com